The purpose of this study is to compare the effectiveness and safety of ABP 501 against Adalimumab (Humira®) in adult subjects with moderate to severe rheumatoid arthritis (RA) who have an inadequate response to methotrexate (MTX).
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01970475?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
